首页> 外文OA文献 >The use of baseline tumor size to prognosticate overall survival in stage IV melanoma patients treated with the PD-1 inhibitor pembrolizumab

【2h】

The use of baseline tumor size to prognosticate overall survival in stage IV melanoma patients treated with the PD-1 inhibitor pembrolizumab

机译：使用基线肿瘤大小以预后于PD-1抑制剂Pembrolizumab治疗的阶段Schanoma患者的总生存率

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Philip Friedlander;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab (vol 24, pg 4960, 2018) [J] . Joseph Richard W., Elassaiss-Schaap Jeroen, Kefford Richard, Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第23期

机译：基线肿瘤大小是用PEMBROLIZUMAB处理的黑色素瘤患者整体存活的独立预后因素（Vol 24，PG 4960，2018）
2. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab [J] . Joseph Richard W., Elassaiss-Schaap Jeroen, Kefford Richard, Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第20期

机译：基线肿瘤大小是用PEMBROLIZUAB治疗黑素瘤患者整体存活的独立预后因素
3. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease [J] . Diem Stefan, Ali Omar Hasan, Ackermann Christoph J., Cancer immunology, immunotherapy : . 2018,第1期

机译：肿瘤浸润淋巴细胞在第III期的淋巴结转移中，对应于IV阶段疾病时患有IPILIMIMAB治疗的九患者的反应和生存
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Cost and survival analysis of treating stage IV non-small cell lung cancer. [D] . Folefac, Edmund. 2015

机译：治疗IV期非小细胞肺癌的费用和生存分析。
6. The use of baseline tumor size to prognosticate overall survival in stage IV melanoma patients treated with the PD-1 inhibitor pembrolizumab [O] . Philip Friedlander 2019

机译：使用基线肿瘤大小预后PD-1抑制剂pembrolizumab治疗的IV期黑色素瘤患者的总体生存
7. Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti–PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors [O] . J.C. Sachdev, S. Hu-Lieskovan, A. Patnaik, 2016

机译：通过将CSF1R抑制剂（PEXIDARTINIB / PLX3397）用抗PD-1抗体（PEMBROLIZUAB）组合治疗先进的黑色素瘤和其他实体肿瘤来研究双免疫抑制阻断的相1 / 2A研究

The use of baseline tumor size to prognosticate overall survival in stage IV melanoma patients treated with the PD-1 inhibitor pembrolizumab

著录项

引文网络

相似文献

相关主题

期刊订阅